FAQs for Prescribers2025-09-09T13:09:15-04:00

Frequently Asked Questions About Arbli™

FAQs for Healthcare Professionals & Prescribers

What is Arbli and its approved indications?2025-09-05T17:40:37-04:00

Arbli is indicated for the treatment of hypertension in adults and children greater than 6 years old, reduction of stroke risk in patients with hypertension and left ventricular hypertrophy, and treatment of diabetic nephropathy in patients with type 2 diabetes and a history of hypertension.1

An angiotensin II receptor blocker (ARB), Arbli is indicated for:

  • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
  • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients.
  • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.1

For product details, see:

What makes Arbli different from other losartan potassium products?2025-09-05T17:42:01-04:00

Arbli is the first FDA-approved, ready-to-use oral liquid formulation of losartan potassium in the United States. It does not require compounding, offers a peppermint-flavored suspension, and is available in a 165 mL bottle with a 24-month (unopened) shelf life that does not require refrigeration.1

View the losartan comparison matrix >

What are the key safety considerations or warnings for Arbli?2025-09-05T17:41:39-04:00

Arbli is contraindicated in patients with hypersensitivity to any component of the product and should not be co-administered with aliskiren in patients with diabetes. It can cause fetal harm if used during pregnancy, especially in the second and third trimesters. Use caution in patients who are volume- or salt-depleted, as they may be at risk for hypotension1.

See section 5 WARNINGS AND PRECAUTIONS in the Full Prescribing Information >

What is the recommended dosing for Arbli?2025-09-05T17:33:16-04:00

Dosing varies by indication and patient population.

  • For adults with hypertension, the usual starting dose is 50 mg once daily
  • For children great than 6 years, the starting dose is 0.7 mg/kg (up to 50 mg) once daily
  • Adjust the dose as needed based on blood pressure response

Consult the full prescribing information for specific dosing recommendations for hypertension, stroke risk reduction, and diabetic nephropathy.1

See section 2 DOSAGE AND ADMINISTRATION in the full prescribing information >

Are there any notable drug interactions with Arbli?2025-09-05T17:29:51-04:00

Yes, Arbli should not be co-administered with aliskiren in patients with diabetes. Other potential interactions include those with potassium supplements, potassium-sparing diuretics, and NSAIDs, which may increase the risk of hyperkalemia and renal impairment.1

For details, see section 7 DRUG INTERACTIONS in the full prescribing information >

What should be done in case of an Arbli overdose?2025-09-05T17:26:43-04:00

Symptoms of overdose may include hypotension and tachycardia. Supportive treatment should be instituted immediately.  If the person is unconscious, having trouble breathing, having a seizure, or can’t be awakened, immediately call emergency services, such as 911.  Contact the Poison Control Helpline at 1-800-222-1222.  Additional information can be found online at https://www.poisonhelp.org/help.  Neither losartan nor its active metabolite can be removed by hemodialysis.1

How should Arbli be administered?2025-09-05T17:27:55-04:00

ArbliTM (losartan potassium) oral suspension, 10 mg/mL, is a white, translucent suspension with a peppermint odor. Instruct patients or caregivers to shake for 20 seconds before each use and to use oral dosing syringe(s) or an oral dosing cup (not included) to measure the prescribed amount of medication. Inform patients that oral dosing syringe(s) or an oral dosing cup may be obtained from their pharmacy.1

For dosage and administration details, visit:

References

  1. ARBLITM [prescribing information]. Commack, NY: Scienture, LLC. 2025

Important Safety Information for Arbli™

Read More…

WARNING: FETAL TOXICITY

When pregnancy is detected, discontinue ARBLI as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

WARNING: FETAL TOXICITY

When pregnancy is detected, discontinue ARBLI as soon as possible.

Important Safety Information for Arbli™

WARNING: FETAL TOXICITY

When pregnancy is detected, discontinue ARBLI as soon as possible. Drugs that act directly on the renin-angiotensin system can cause injury and death to the developing fetus.

INDICATIONS
ARBLI is an angiotensin II receptor blocker (ARB) indicated for:

  • Treatment of hypertension, to lower blood pressure in adults and children greater than 6 years old. Lowering blood pressure reduces the risk of fatal and nonfatal cardiovascular events, primarily strokes and myocardial infarctions.
  • Reduction of the risk of stroke in patients with hypertension and left ventricular hypertrophy. There is evidence that this benefit does not apply to Black patients.
  • Treatment of diabetic nephropathy with an elevated serum creatinine and proteinuria in patients with type 2 diabetes and a history of hypertension.

CONTRAINDICATIONS
ARBLI is contraindicated in patients who are hypersensitive to any component of this product.  ARBLI is also contraindicated for co-administration with aliskiren in patients with diabetes. 

WARNINGS AND PRECAUTIONS
Fetal Toxicity: ARBLI can cause fetal harm when administered to a pregnant woman. When pregnancy is detected, discontinue ARBLI as soon as possible
Hypotension: In patients with an activated renin-angiotensin system, such as volume- or salt-depleted patients, symptomatic hypotension may occur after initiation of treatment with ARBLI.  Correct volume or salt depletion prior to administration of ARBLI.
Renal Function Deterioration:  Patients whose renal function may depend in part on the activity of the renin-angiotensin system (e.g., patients with renal artery stenosis, chronic kidney disease, severe congestive heart failure, or volume depletion) may be at particular risk of developing acute renal failure on ARBLI.  Monitor renal function and potassium in susceptible patients.
Hyperkalemia: Monitor serum potassium periodically and treat appropriately. Dosage reduction or discontinuation of ARBLI may be required.  Concomitant use of other drugs that may increase serum potassium may lead to hyperkalemia.

ADVERSE REACTIONS
The most common adverse reactions (incidence ≥2% and greater than placebo) are: dizziness, upper respiratory infection, nasal congestion, and back pain.

DRUG INTERACTIONS
Agents Increasing Serum Potassium: Risk of hyperkalemia; monitor serum potassium.
Lithium: Risk of lithium toxicity.
NSAIDs Including COX-2 Inhibitors: Increased risk of renal impairment and reduced diuretic, natriuretic, and antihypertensive effects.
Dual Blockade of the Renin-Angiotensin System: Increased risk of renal impairment, hypotension, syncope, and hyperkalemia. Do not co-administer aliskiren with losartan in patients with diabetes or renal impairment.

USE IN SPECIFIC POPULATIONS

Pregnancy
ARBLI can cause fetal harm when administered to a pregnant woman. Use of drugs that act directly on the renin-angiotensin system during the second and third trimesters of pregnancy reduces fetal renal function and increases fetal and neonatal morbidity and death. When pregnancy is detected, discontinue losartan as soon as possible.

Lactation
Advise not to breastfeed during treatment with ARBLI and for 2 days after the last dose.

Pediatric Patients
Antihypertensive effects of ARBLI have been established in hypertensive pediatric patients aged 6 to 16 years. ARBLI is not recommended in pediatric patients less than 2 years of age or in pediatric patients with glomerular filtration rate less than 30 mL/min/1.73 m2.

Hepatic Impairment
For patients with mild-to-moderate hepatic impairment the recommended starting dose is 25 mg once daily. Not studied in patients with severe hepatic impairment.

This Important Safety Information does not include all of the information needed to use ARBLI safely and effectively.  Please see Full Prescribing Information, including BOXED WARNING.

To report SUSPECTED ADVERSE REACTIONS, contact Scienture, LLC at 1-833-754-4917 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

Content on this website is intended only for United States residents. Product labeling, packaging, and images are representative only. Images of healthcare providers, patients and caregivers on this site are not actual providers and patients. Arbli™ is a trademark of Scienture, LLC. Manufactured in the U.S.A.

COZAAR® is a registered trademark of N.V. Organon.

© Scienture, LLC. All Rights Reserved. All trademarks referred to are the property of their respective owners.

Scienture logo

US-ARBLI™-0000103

September 2025

Go to Top